[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 49 of about 49
1. Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS: Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med; 2003 Jan 21;138(2):90-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer.
  • BACKGROUND: Although the efficacy of adjuvant chemotherapy in prolonging survival for women with breast cancer has been well documented, limited population-based information is available on the actual use of chemotherapy.
  • OBJECTIVE: To examine the relationship between age and chemotherapy use.
  • PATIENTS: 5101 women 20 years of age or older receiving a diagnosis of stage I, stage II, or stage IIIA breast cancer from 1991 through 1997.
  • MEASUREMENTS: Pattern of chemotherapy use by age; logistic regression analysis to generate the odds and probabilities of receiving chemotherapy; and sensitivity analysis to estimate potential effects of unmeasured confounders.
  • RESULTS: Overall, 29% of women received chemotherapy.
  • The rate of chemotherapy use for women with stage I, stage II, or stage IIIA breast cancer was 11%, 47%, and 68%, respectively.
  • Across all tumor stages, the use of chemotherapy decreased substantially with increasing age (P < 0.001).
  • Overall, 66% of women younger than 45 years of age received chemotherapy compared with 44% of women between 50 and 54 years of age, 31% of women between 55 and 59 years of age, and 18% of women between 60 and 64 years of age.
  • The decreasing pattern of chemotherapy use with age continued after adjustment for prognostic factors and was relatively insensitive to changes in unmeasured factors.
  • CONCLUSIONS: There is considerable discrepancy between the 1990 National Institutes of Health Consensus Conference recommendations for chemotherapy administration in women with breast cancer and the actual use of chemotherapy in the community.
  • The decrease in use with age may relate to the decreasing efficacy of chemotherapy with age, as reported in clinical trials.
  • Outcomes studies should address whether the recommendations are overly aggressive or whether practicing oncologists are too conservative in their use of chemotherapy.
  • [MeSH-major] Breast Neoplasms / drug therapy. Chemotherapy, Adjuvant / utilization. Guideline Adherence. Practice Guidelines as Topic
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Confounding Factors (Epidemiology). Female. Humans. Menopause. Middle Aged. Multivariate Analysis. National Institutes of Health (U.S.). Neoplasm Staging. Regression Analysis. Sensitivity and Specificity. United States

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):269-71 [10655446.001]
  • [Cites] Oncology (Williston Park). 2000 Nov;14(11A):33-49 [11195418.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1455-61 [11230491.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 4;93(13):979-89 [11438563.001]
  • [Cites] BMJ. 2001 Jul 21;323(7305):155-7 [11463690.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):730-7 [11550141.001]
  • [Cites] JAMA. 2001 Sep 26;286(12):1461-7 [11572738.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(30):62-6 [11773294.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4636-42 [12488407.001]
  • [Cites] Surg Gynecol Obstet. 1984 Oct;159(4):309-18 [6484787.001]
  • [Cites] JAMA. 1985 Dec 27;254(24):3461-3 [4068189.001]
  • [Cites] Health Serv Res. 1986 Feb;20(6 Pt 2):961-76 [3949543.001]
  • [Cites] JAMA. 1986 Jun 27;255(24):3385-90 [3712698.001]
  • [Cites] J Gerontol. 1987 Mar;42(2):185-90 [3819344.001]
  • [Cites] JAMA. 1987 May 22-29;257(20):2766-70 [3573271.001]
  • [Cites] JAMA. 1987 Jul 24-31;258(4):516 [3599351.001]
  • [Cites] JAMA. 1988 Jun 17;259(23):3413-7 [3373679.001]
  • [Cites] Arch Intern Med. 1988 Oct;148(10):2258-60 [3178383.001]
  • [Cites] N Engl J Med. 1988 Dec 29;319(26):1681-92 [3205265.001]
  • [Cites] JAMA. 1991 Jan 16;265(3):391-5 [1984541.001]
  • [Cites] JAMA. 1991 Dec 25;266(24):3433-8 [1688350.001]
  • [Cites] Lancet. 1992 Jan 4;339(8784):1-15 [1345950.001]
  • [Cites] JAMA. 1992 Jul 1;268(1):57-62 [1608114.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):594-601 [8319193.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] J Am Coll Surg. 1994 Mar;178(3):213-9 [8149010.001]
  • [Cites] Cancer. 1994 Oct 1;74(7 Suppl):2165-71 [8087784.001]
  • [Cites] Semin Oncol. 1995 Feb;22(1 Suppl 1):14-6 [7863346.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1031-8 [8683633.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 19;89(22):1673-82 [9390536.001]
  • [Cites] CMAJ. 1998 Feb 10;158 Suppl 3:S43-51 [9484278.001]
  • [Cites] CMAJ. 1998 Feb 10;158 Suppl 3:S52-64 [9484279.001]
  • [Cites] N Engl J Med. 1998 Oct 1;339(14):974-84 [9753714.001]
  • [Cites] Lancet. 1998 Sep 19;352(9132):930-42 [9752815.001]
  • [Cites] BMJ. 1999 Feb 20;318(7182):527-30 [10024268.001]
  • [Cites] J Clin Epidemiol. 1999 May;52(5):463-70 [10360342.001]
  • [Cites] CA Cancer J Clin. 1999 May-Jun;49(3):159-77 [10445015.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 1999 Sep;54(9):M474-8 [10536651.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [CommentIn] Ann Intern Med. 2003 Nov 18;139(10):868; author reply 868-9 [14623632.001]
  • [CommentIn] Ann Intern Med. 2003 Nov 18;139(10):867-8; author reply 868-9; discussion 869 [14623631.001]
  • [ErratumIn] Ann Intern Med. 2003 Nov 18;139(10):873
  • [SummaryForPatientsIn] Ann Intern Med. 2003 Jan 21;138(2):I16 [12529113.001]
  • (PMID = 12529090.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090626-02S1; United States / NCI NIH HHS / CA / R01 CA090626; United States / NCI NIH HHS / CA / R01 CA090626-03; United States / NCI NIH HHS / CA / R01 CA090626-04; United States / NCI NIH HHS / CA / R01-CA90626; United States / NCI NIH HHS / CA / R01-CA871773; United States / NIA NIH HHS / AG / P30 AG024832; United States / NCI NIH HHS / CA / R01 CA090626-01; United States / NCI NIH HHS / CA / R01 CA090626-03S1; United States / NCI NIH HHS / CA / R01 CA090626-02
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS71344; NLM/ PMC2566742
  •  go-up   go-down


2. Alvarado-Miranda A, Arrieta O, Gamboa-Vignolle C, Saavedra-Perez D, Morales-Barrera R, Bargallo-Rocha E, Zinser-Sierra J, Perez-Sanchez V, Ramirez-Ugalde T, Lara-Medina F: Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer. Radiat Oncol; 2009;4:24
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.
  • BACKGROUND: Despite broad advances in multimodal treatment of locally advanced breast cancer (LABC), 30 to 40% of patients develop loco-regional relapse.
  • The aim of this study was to analyze in a retrospective manner the effectiveness of concurrent chemo-radiotherapy (CCRTh) after neoadjuvant chemotherapy (NCT) in patients with LABC.
  • METHODS: One hundred twelve patients with LABC (stage IIB-IIIB) were treated with NCT (5-fluorouracil 500 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2 (FAC), or doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (AC) IV in four 21-day courses) followed by CCRTh (60 Gy breast irradiation and weekly mitomycin 5 mg/m2, 5-fluorouracil 500 mg/m2, and dexamethasone 16 mg, or cisplatin 30 mg/m2, gemcitabine 100 mg/m2 and dexamethasone 16 mg), and 6-8 weeks later, surgery and two additional courses of FAC, AC, or paclitaxel 90 mg/m2 weekly for 12 weeks, and in case of estrogen-receptor positive patients, hormonal therapy.
  • RESULTS: Stages IIB, IIIA and -B were 21.4, 42.9, and 35.7%, respectively.
  • Pathological complete response (pCR) in the breast was 42% (95% CI, 33.2-50.5%) and, 29.5% (95% CI, 21.4-37.5%) if including both the breast and the axillary nodes.
  • Multivariate analysis demonstrated that the main DFS determinant was clinical stage (IIB and IIIA vs. IIIB, HR=3.1; 95% CI, 1.02-9.74; p=0.04).
  • CONCLUSION: This non-conventional multimodal treatment has good loco-regional control for LABC.
  • Randomized clinical trials of preoperative CCRTh following chemotherapy, in patients with LABC are warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / radiotherapy. Neoadjuvant Therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] Cancer. 1983 May 15;51(10):1826-9 [6831348.001]
  • [Cites] Ann Surg. 1965 Jan;161:103-4 [14252619.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):116-26 [15657341.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):817-23 [15708261.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):351-7 [15890574.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7098-104 [16192593.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jan;95(2):147-52 [16319989.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2268-75 [16618947.001]
  • [Cites] Med Oncol. 2006;23(2):171-83 [16720917.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14):2286-95 [16893641.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1306-12 [16750318.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):405-10 [17264336.001]
  • [Cites] BMC Cancer. 2007;7:36 [17324279.001]
  • [Cites] J Cancer Res Ther. 2005 Jul-Sep;1(3):129-31 [17998642.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):778-85 [18258986.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):786-90 [18258987.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):465-72 [17986623.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):705-9 [18191333.001]
  • [Cites] J Thorac Oncol. 2009 Jul;4(7):845-52 [19487963.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2692-9 [10561343.001]
  • [Cites] Int J Cancer. 2001 Aug 20;96(4):253-9 [11474500.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4224-37 [11709566.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1225-33 [12128124.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Cancer. 1988 Dec 15;62(12):2507-16 [3056604.001]
  • [Cites] J Natl Cancer Inst. 1990 Oct 3;82(19):1539-45 [2402015.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):591-5 [7993833.001]
  • [Cites] Oncologist. 2003;8(6):521-30 [14657530.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):301-6 [14760126.001]
  • [Cites] Breast J. 2004 May-Jun;10(3):204-10 [15125746.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6622-8 [15475452.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • (PMID = 19591689.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2716349
  •  go-up   go-down


3. Peppercorn J, Herndon J 2nd, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E: Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer; 2005 Oct 15;104(8):1580-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
  • BACKGROUND: The objective of this study was to compare the quality of life (QOL) after treatment among patients who had breast carcinoma with multiple positive lymph nodes.
  • The patients were randomized to receive either high-dose chemotherapy with autologous stem cell support (HDC) or intermediate-dose chemotherapy (IDC) in the adjuvant setting.
  • METHODS: Two hundred forty-six patients with AJCC Stage IIA, IIB, or IIIA breast carcinoma who had > or = 10 positive lymph nodes and who were participants in Cancer and Leukemia Group B (CALGB) 9082 were enrolled in this companion study, CALGB 9066.
  • Patients were randomized to receive either high-dose cyclophosphamide, carmustine, and cisplatin (CPA/cDDP/BCNU) and autologous bone marrow transplantation (the HDC arm) or intermediate-dose CPA/cDDP/BCNU as consolidation to adjuvant chemotherapy (the IDC arm).
  • QOL was assessed at baseline and at 3 months, 12 months, 24 months, and 36 months using the Functional Living Index-Cancer (FLIC), the Psychosocial Adjustment to Illness Scale (PAIS)-Self Report, and the McCorkle Symptom Distress Scale (SDS).
  • CONCLUSIONS: Patients who received more intensive adjuvant therapy experienced transient declines in QOL.
  • By 12 months after therapy, QOL was comparable between the 2 arms, regardless of therapy intensity, and many QOL areas were improved from baseline.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation. Breast Neoplasms / therapy. Quality of Life
  • [MeSH-minor] Adolescent. Adult. Carmustine / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Female. Humans. Middle Aged. Neoplasm Staging. Survival Rate. Time Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16118805.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA04457; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA31809; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / CA37135; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA47545; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA60138; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77651
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


Advertisement
4. Fujitomi Y, Fujiyoshi K, Yasue K: [Improved QOL with cancer chemotherapy in two patients with breast cancer suffering form carcinomatous pleurisy and carcinomatous peritonitis]. Gan To Kagaku Ryoho; 2000 Feb;27(2):303-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improved QOL with cancer chemotherapy in two patients with breast cancer suffering form carcinomatous pleurisy and carcinomatous peritonitis].
  • One of the breast cancer patients introduced here suffered from recurrent carcinomatous pleurisy and the other from recurrent carcinomatous peritonitis.
  • The patient with recurrent carcinomatous pleurisy was a 47-year-old female with stage IIIa breast cancer.
  • She underwent a standard mastectomy and, following surgery, radiotherapy (50 Gy) and CAF therapy (30 mg of ADM, 1,800 mg of futraful and 100 mg of CPA, administered p.o.).
  • CAF therapy was performed.
  • At present, after one year and 7 months, the patient is receiving outpatient treatment and remains under observation.
  • The breast cancer was detected in a diagnosis of metastasis to the axillary lymph nodes.
  • It is anticipated that chemotherapy for carcinomatous pleurisy and carcinomatous peritonitis will contribute to an improvement in patients' QOL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Peritonitis / drug therapy. Pleurisy / drug therapy. Quality of Life
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Medroxyprogesterone Acetate / administration & dosage. Middle Aged. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10700906.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; C2QI4IOI2G / Medroxyprogesterone Acetate; U3P01618RT / Fluorouracil; 1-UFT protocol; CAF protocol
  •  go-up   go-down


5. Ataergin S, Arslan N, Ozet A, Ozguven MA: Abnormal 18F-FDG Uptake Detected with Positron Emission Tomography in a Patient with Breast Cancer: A Case of Sarcoidosis and Review of the Literature. Case Rep Med; 2009;2009:785047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal 18F-FDG Uptake Detected with Positron Emission Tomography in a Patient with Breast Cancer: A Case of Sarcoidosis and Review of the Literature.
  • We describe a female patient with stage IIIA breast cancer in first complete remission with combination chemotherapy who developed nodular formations in the lung and axilla 12 years later.
  • She was first given combination chemotherapy and hormonal therapy but was proven thereafter to have sarcoidosis by pathologic examination and was successfully treated with corticosteroid treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Nucl Med. 2008 Apr;33(4):258-61 [18356663.001]
  • [Cites] J Nucl Med. 2001 Mar;42(3):432-45 [11337520.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2005 Apr;53(4):196-8 [15875553.001]
  • [Cites] Radiographics. 1999 Jan-Feb;19(1):61-77; quiz 150-1 [9925392.001]
  • [Cites] Clin Nucl Med. 1998 Nov;23(11):739-42 [9814559.001]
  • [Cites] Clin Nucl Med. 1996 Dec;21(12):941-9 [8957608.001]
  • [Cites] Chest. 1996 Apr;109(4):982-8 [8635381.001]
  • [Cites] Eur J Nucl Med. 1994 Apr;21(4):297-305 [8005153.001]
  • [Cites] Chest. 1993 Oct;104(4):997-1002 [8404239.001]
  • [Cites] J Nucl Med. 1992 Nov;33(11):1972-80 [1432158.001]
  • [Cites] Nouv Presse Med. 1977 Apr 9;6(14):1213-5 [857243.001]
  • [Cites] J Nucl Med. 1974 Dec;15(12):1145-8 [4610098.001]
  • [Cites] Semin Nucl Med. 2004 Apr;34(2):122-33 [15031812.001]
  • [Cites] Mol Imaging Biol. 2003 Jan-Feb;5(1):15-9 [14499156.001]
  • [Cites] Radiographics. 2003 Mar-Apr;23(2):315-40; quiz 533 [12640150.001]
  • [Cites] J Nucl Med. 2002 Feb;43(2):167-72 [11850480.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] Clin Nucl Med. 2007 Mar;32(3):262-4 [17314619.001]
  • (PMID = 19812702.001).
  • [ISSN] 1687-9627
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2755327
  •  go-up   go-down


6. Vlastos G, Mirza NQ, Lenert JT, Hunt KK, Ames FC, Feig BW, Ross MI, Buzdar AU, Singletary SE: The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer; 2000 Mar 15;88(6):1417-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
  • BACKGROUND: Induction chemotherapy (IC) has become the standard of care for locally advanced breast carcinoma, frequently downstaging both the primary tumor and the axilla, and making patients eligible for less invasive surgical procedures.
  • The usefulness of IC in earlier stage operable breast carcinoma is now being considered.
  • METHODS: This study involved a subset of 129 patients from a series of 174 with T2-3, N0-1, M0 or T1, N1, M0 breast carcinoma (Stage IIA, IIB, or IIIA ) who were registered in a prospective IC trial using paclitaxel or a combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC).
  • The subset included patients who had received no preoperative radiation therapy but had completed 3-5 cycles of induction chemotherapy and had undergone a Level I-II axillary lymph node dissection.
  • The objective was to evaluate the effectiveness of induction chemotherapy with paclitaxel or FAC in downstaging the primary tumor and axillary metastases in these early stage breast carcinoma patients.
  • Among patients clinically classified as N1, 34% became histologically negative and 38% had only 1-3 positive lymph nodes after induction chemotherapy.
  • CONCLUSIONS: IC with paclitaxel or FAC resulted in effective downstaging of primary tumors and axillary metastases in patients with Stage IIA, IIB, and IIIA breast carcinoma.
  • However, a significant proportion of patients still had residual but low volume microscopic disease; such disease status may allow minimally invasive surgical approaches to locoregional therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / surgery. Carcinoma / surgery. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chi-Square Distribution. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Feasibility Studies. Female. Fluorouracil / administration & dosage. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Staging. Neoplasm, Residual. Paclitaxel / therapeutic use. Prospective Studies. Radiotherapy, Adjuvant. Remission Induction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10717625.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Rozenowicz Rde L, Santos RE, Silva MA, Rodrigues FF, Oliveira AL, Ulson LB, Oliveira VM, Aoki T: Cox-2 and its association with prognostic factors and response to primary chemotherapy in patients with breast cancer. Rev Col Bras Cir; 2010 Oct;37(5):323-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cox-2 and its association with prognostic factors and response to primary chemotherapy in patients with breast cancer.
  • OBJECTIVE: To evaluate the immunohistochemical expression of cox-2 before primary chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and its association with initial tumor size, lymph node status, hormone receptors, expression of HER2 and the clinical and pathological response in patients with breast cancer.
  • METHODS: We conducted a retrospective study with 41 women with histopathological diagnosis of ductal breast carcinoma.
  • They underwent primary chemotherapy with FEC regimen (5-fluorouracil, epirubicin and cyclophosphamide) at 500mg/m2, 75mg/m2 and 500 mg/m2, respectively.
  • Inclusion criteria were age range between 30 and 70 years, stage II to IIIA, absence of metastasis, primary tumor of the breast, single, unilateral, with ductal invasion at histology and absence of heart disease and pregnancy.
  • The evaluation of clinical response to treatment was performed during physical examination by measuring the major tumor axis with a pachymeter.
  • Measurements were taken at admission and after primary chemotherapy cycles.
  • After three chemotherapy sessions at intervals of 21 days the surgical procedure was carried out.
  • RESULTS: The distribution according to UICC clinical stage classified six patients in stage IIA (14.6%), 22 in stage IIB (53.6%) and 13 stage IIIA (31.8%).
  • CONCLUSION: There was an association of the expression of Cox-2 to the factors associated with poor prognosis in breast cancer, such as positive lymph node status, negative hormone receptors and HER2 expression.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / enzymology. Carcinoma, Ductal, Breast / enzymology. Carcinoma, Ductal, Breast / etiology. Cyclooxygenase 2 / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21180996.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


8. Conti F, Carpano S, Sergi D, Di Lauro L, Amodio A, Vici P, Abbate MI, Ferranti FR, Viola G, Botti C, Foggi P, Sperduti I, Lopez M: [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results]. Clin Ter; 2007 Jul-Aug;158(4):331-41
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
  • [Transliterated title] CEF (ciclofosfamide, epirubicina, fluorouracile) ad alte dosi come chemioterapia primaria nel trattamento del carcinoma mammario localmente avanzato: risultati a lungo termine.
  • PURPOSE: To determine wether primary CEF is effective in locally advanced breast cancer, as measured by response, local recurrences, disease free survival (DFS) and overall survival (OS).
  • MATERIAL AND METHODS: From 1990 to 1998, 62 patients with stage III disease were enrolled into a prospective study at Regina Elena Institute for Cancer Research, Rome.
  • Inflammatory breast cancer (IBC) was included.
  • Patients received three 21 days cycles of chemotherapy that consisted in epirubicin 50 mg/m2, cyclophosphamide 400 mg/m2, and fluorouracil 500 mg/m2 i.v. on days 1 and 8.
  • After primary chemotherapy, whenever possible, mastectomy or conservative surgery was performed.
  • Subsequently responding patients received the same regimen, while non responders were given a non cross resistant chemotherapy.
  • In case of conservative surgery or initial T4 tumor radiation therapy was performed at the end of adjuvant chemotherapy.
  • RESULTS: Seven IIIA patients had a median OS of 43 months (C.I.
  • Forty IIIB non inflammatory breast cancer patients had a median DFS of 87 months (C.I.
  • Ten-year OS was 28.6% for stage IIIA, 50.6% for stage IIIB and 36% for IBC.
  • CONCLUSION: Primary CEF appear to be an effective treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Agents, Hormonal / administration & dosage. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17953285.001).
  • [ISSN] 0009-9074
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] ita
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Fornasiero A, Ghiotto C, Daniele O, Favaretto AG, D'Amanzo P, Ziade A: Neoadjuvant moderately high-dose chemotherapy with rh-G-CSF in locally advanced breast carcinoma. Tumori; 2001 Jul-Aug;87(4):223-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant moderately high-dose chemotherapy with rh-G-CSF in locally advanced breast carcinoma.
  • The poor results of local treatment for locally advanced breast carcinoma (LABC) justify the use of chemotherapy as primary treatment.
  • Retrospective studies have shown a positive correlation between dose and response rate in advanced breast cancer.
  • G-CSF has shown efficacy in achieving optimal dose intensity and ameliorating chemotherapy-induced myelosuppression.
  • The aim of the present study was to assess the efficacy of a moderately high-dose chemotherapy regimen in terms of response rate, disease-free and overall survival and to assess the role of G-CSF in induced neutropenia.
  • METHODS: Inclusion criteria were the following: age <65 years, WHO performance status <2, histologically proven breast carcinoma, adequate hematologic, renal and hepatic function, stage IIIA or IIIB disease, and no metastatic disease.
  • No prior chemotherapy or radiotherapy was allowed.
  • Three cycles of the following chemotherapy were used preoperatively: epirubicin (100 mg/m2 on day 1), cyclophosphamide (400 mg/m2 for 3 consecutive days) and rh-G-CSF (5 microg/kg/die from day 4 to day 12 every 14 days).
  • After mastectomy or quadrantectomy plus radiotherapy, all patients were treated with 4 courses of adjuvant chemotherapy according to the CMF 1-8 schedule (methotrexate, 40 mg/m2 cyclophosphamide, 600 mg/m2; fluorouracil, 600 mg/m2; all on days 1 and 8, with recycle every 4 weeks).
  • Thirty-five patients had stage IIIA and 22 patients stage IIIB disease (7 with inflammatory disease).
  • The overall 5-year survival rate was 76% (standard error--SE), 6%) and the 5-year disease-free survival rate was 68% (SE, 6.3%).
  • CONCLUSIONS: The 14-day regimen was well tolerated and effective in LABC patients, although not superior to standard-dose chemotherapy.
  • To improve results the use of new drugs in controlled clinical trials seems warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Granulocyte Colony-Stimulating Factor / therapeutic use. Neutropenia / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Female. Filgrastim. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Humans. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Middle Aged. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11693799.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF regimen
  •  go-up   go-down


10. Espinosa E, Morales S, Borrega P, Casas A, Madroñal C, Machengs I, Illarramendi JA, Lizón J, Moreno JA, Belón J, Janáriz J, de la Puente M, Checa T, Mel JR, González Barón M: Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemother Pharmacol; 2004 Dec;54(6):546-52
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer.
  • PURPOSE: Epirubicin and docetaxel are two of the most active drugs against breast carcinoma.
  • As the achievement of a pathological complete response (pCR) is important for survival of patients with locally advanced disease, we used both drugs as neoadjuvant chemotherapy.
  • PATIENTS AND METHODS: Women with locally advanced or inflammatory breast cancer received epirubicin 120 mg/m2 followed by docetaxel 75 mg/m2, both on day 1, every 21 days for four cycles.
  • The median age was 47 years, tumour stage was IIIA in 14 patients and IIIB in 36.
  • One patient progressed and died soon after the end of chemotherapy.
  • CONCLUSIONS: Docetaxel plus high-dose epirubicin showed promising activity in patients with locally advanced and inflammatory breast cancer, at the cost of moderate toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Epirubicin / administration & dosage. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Middle Aged. Neoadjuvant Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316749.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


11. Moyses B, Haegele P, Rodier JF, Lehmann S, Petit T, Velten M, Schraub S: Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer. Clin Breast Cancer; 2002 Jan;2(4):304-10
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer.
  • Breast helical computed tomography (CT) was evaluated for use in assessing response to neoadjuvant chemotherapy and residual tumor volume.
  • Forty-three patients with large, inflammatory breast cancers (stage IIA, 12; IIB, 13; IIIA, 9; IIIB, 9), all histologically confirmed by core biopsy, were evaluated prior to and following neoadjuvant chemotherapy.
  • The breast helical CT procedure involved patients in the prone position using single acquisition during quiet respiration following intravenous injection of nonionic contrast material.
  • All tumors were clearly visible by breast helical CT, showing important tumor enhancement.
  • Helical CT evaluation of response to chemotherapy (using World Health Organization criteria) corresponded better with mammography (78%, Cohen's kappa statistic (kappa) = 0.65) than with clinical examination (53%, kappa = 0.30).
  • Helical CT measurement of residual tumor volume after neoadjuvant chemotherapy and correlation with pathologic findings were globally satisfactory.
  • Breast helical CT can be very useful in the quantitative assessment of response to neoadjuvant chemotherapy and preoperative determination of residual tumor volume.
  • For this reason, it can be considered an alternative to breast magnetic resonance imaging because of its simplicity, rapidity, and accessibility.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Ductal, Breast / diagnostic imaging. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / diagnostic imaging. Carcinoma, Lobular / drug therapy. Drug Monitoring / methods. Neoadjuvant Therapy. Paclitaxel / analogs & derivatives. Taxoids. Tomography, X-Ray Computed / standards. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Biopsy, Needle. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Mammography / standards. Mastectomy. Middle Aged. Mitoxantrone / administration & dosage. Physical Examination / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11899363.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; P88XT4IS4D / Paclitaxel; Q6C979R91Y / vinorelbine; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Stemmer SM, Rizel S, Hardan I, Adamo A, Neumann A, Goffman J, Brenner HJ, Pfeffer MR: The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study. J Clin Oncol; 2003 Jul 15;21(14):2713-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study.
  • PURPOSE: This phase II single-institution prospective, nonrandomized trial investigates high-dose adjuvant chemotherapy and locoregional radiotherapy in patients with breast cancer.
  • PATIENTS AND METHODS: 100 patients with high-risk stage II-III breast cancer received doxorubicin-based adjuvant chemotherapy followed by high-dose chemotherapy, stem-cell support, and locoregional radiotherapy.
  • There was no treatment related mortality.
  • CONCLUSION: In patients with high-risk stage II to III breast cancer, the inclusion of the IMN in the radiotherapy field was associated with a statistically significant increase in DFS and a borderline increase in OS.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / radiotherapy. Carcinoma / pathology. Carcinoma / radiotherapy. Lymphatic Irradiation
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Mastectomy / methods. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Prospective Studies. Risk Assessment. Single-Blind Method. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2004 Jun 1;22(11):2257-8; author reply 2258 [15169822.001]
  • [CommentIn] J Clin Oncol. 2004 Jun 1;22(11):2258-9; author reply 2259-60 [15169824.001]
  • (PMID = 12860949.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Julian TB, Dusi D, Wolmark N: Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg; 2002 Oct;184(4):315-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer.
  • BACKGROUND: After neoadjuvant chemotherapy, while results of sentinel node biopsy (SNB) are encouraging, conditions that may affect sentinel node (SN) detection and false negative rates with respect to clinical and pathological tumor response after neoadjuvant therapy require investigation.
  • METHODS: Thirty-four patients with clinical stage I, II and IIIA invasive breast cancer underwent neoadjuvant chemotherapy with doxorubicin/cyclophosphamide or doxorubicin/cyclophosphamide and docetaxel/segmental resection, SNB, and axillary node dissection (AND).
  • CONCLUSIONS: SN identification rate and accuracy after neoadjuvant chemotherapy for breast carcinoma were extremely good however there is potential for inaccuracy after less than complete pathological tumor response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Axilla. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Mastectomy. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Predictive Value of Tests. Remission Induction. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12383891.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kouzminova NB, Aggarwal A, Aggarwal S, Lin AY: The impact of residual cancer removed during subsequent surgeries on the outcome of patients with localized breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of residual cancer removed during subsequent surgeries on the outcome of patients with localized breast cancer.
  • : e11533 Background: A close or positive margin after breast cancer surgery is an important risk factor for local recurrence.
  • A significant percentage of breast cancer patients need additional surgeries to obtain clear margins.
  • This study evaluated the impact of residual cancer (RC) found upon subsequent operations on the outcome of the patients with localized breast cancer.
  • METHODS: Under IRB approved protocol, we retrospectively analyzed data on 573 patients with stage I-IIIA breast cancer treated at our institution during 1994-2004.
  • 202 patients had complete tumor removal at single procedure with clear margins, 319 patients had subsequent surgery due to initially compromised margins and 52 patients with compromised margins did not have second surgery.
  • The risk of DR was higher in patients with RC found upon second surgery compared to those who had single procedure breast cancer removal (22.6% vs. 9.9%; HR 2.4, 95% CI 1.3-4.4, p=0.006).
  • Delay in adjuvant chemotherapy due to need for subsequent surgeries strongly correlated with earlier DR in patients with invasive RC found on subsequent operations (r<sub>S</sub> = - 0.55, p = 0.019, two-tailed).
  • CONCLUSIONS: Invasive residual carcinoma found during subsequent surgery after initial compromised margin is an important prognostic factor for DR and DSS, even after clear margins are eventually achieved.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964678.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Mates M, Hopman W, Madarnas Y: Patterns of care and outcomes of locally advanced breast cancer at the Cancer Centre of Southeastern Ontario. J Clin Oncol; 2009 May 20;27(15_suppl):e11614

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of care and outcomes of locally advanced breast cancer at the Cancer Centre of Southeastern Ontario.
  • : e11614 Background: Preoperative chemotherapy (PCT) is the standard of care for locally advanced breast cancer (LABC).
  • METHODS: We reviewed electronic and paper records for M<sub>0</sub> pts receiving PCT for LABC between 1995-2007 at our institution, collecting demographic, disease and treatment-related, and outcome variables.
  • Stage distribution: 10% IIB, 11% IIIA, 77% IIIB and 2% IIIC, of which 45% had inflammatory breast cancer (IBC).
  • At biopsy 90% were invasive ductal carcinoma, 36% were ER and PR(-) and 25% were her2(+).
  • Median time from surgical consultation to PCT was 22d (6-126).
  • PCT was anthracycline-based alone in 85% of pts, 8% received a taxane, 3% also received preop endocrine therapy (ET), no pts received trastuzumab (T) preop.
  • Local therapy: mastectomy (M) in 82% of pts and partial M in 11%.
  • Axillary surgery was done in only 92% of pts (axillary node dissection 90%, sentinel node biopsy 1pt) and 7% had no definitive breast or axillary surgery due to local progression (3) or refusal (1).
  • Postop systemic therapy: CT in 5% of pts, ET in 65% and T in 10% of pts.
  • At definitive surgery 10% of pts had no residual disease in breast or axilla and 3 pts had only DCIS present, for a pathologic (p)CR rate of 15% using MDACC criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961135.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Khosravi-Shahi P, Izarzugaza Peron Y, Perez-Manga G: Low pathologic complete response (pCR) rate to neoadjuvant chemotherapy in invasive lobular carcinoma of breast: Analysis of subgroup of four phase II trials. J Clin Oncol; 2009 May 20;27(15_suppl):601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low pathologic complete response (pCR) rate to neoadjuvant chemotherapy in invasive lobular carcinoma of breast: Analysis of subgroup of four phase II trials.
  • : 601 Background: Pathologic complete response (pCR) after preoperative chemotherapy (PCT) is associated with better outcome in locally advanced breast cancer (LABC).
  • METHODS: Patients (p) with histologically confirmed lobular carcinoma (LC), including in four phase II trials (AT, ATX, TXH, and BTX) conducted in our center, were eligible.
  • Radiotherapy (RT) and hormone therapy (Ht) were allowed after surgery.
  • Secondary endpoints were: clinical response rate (CRR), breast conservative surgery rate (BCSR), pathologic tumoral size (pTS), disease-free survival (DFS), and overall survival (OS).
  • Sixteen ps had LC (16/185 = 8.65%): median age = 50 y (38-66); premenopausal = 56.2%; left breast = 56.2%; median clinical (c) tumor size = 5 cm (3-6); stage:IIA = 6.7%; IIB = 26.7%; IIIA = 33.3%; IIIB = 33.3%; T:cT3 = 50%; cT4 = 28.6%; cN+ = 71.4% (median pN = 2 [0-32]); grade: G2 = 60%, G3 = 40%; ER+ = 78.6%; PgR+ = 64.3%; HER-2+ = 6.25%; phenotype by IHC: Luminal (HR+/HER-2-) = 75% (12/16); Luminal/HER-2+ (HR+/HER-2+) = 6.25%; triple negative (3/16) = 18.75%; p53+ = 25%; EGFR negative = 90%; median Ki-67 = 20% (5-70); adjuvant trastuzumab (H) = 6.25%; RT = 60%, median dose = 50Gy; Ht = 78.6% (tamoxifen = 55%; AI = 45%); type of PCT: docetaxel (T), capecitabine (X), and H (TXH) = 1p (6.2%); doxorubicin (A), T, and X (ATX) = 5 ps (31.2%); bevacizumab, T, and X (BTX) = 5 ps (31.2%); AT = 5 ps (31.2%); median of 5 cycles (2-6).
  • Primary End-Point: Only 1 p (6.25%) had pCR in breast and nodes, and another p had a pCR only in breast, but not in nodes (pCR in breast = 2/16).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961466.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S, Nomura Y, Miura S, Kimijima I, Tashiro H, Ohashi Y, Adjuvant CEF Research Group for Breast Cancer: Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. Breast Cancer; 2010 Jul;17(3):190-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
  • BACKGROUND: To compare the cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy and the anthracycline-containing regimen cyclophosphamide, epirubicin, and fluorouracil (CEF) to evaluate the efficacy and safety of the latter.
  • METHODS: A total of 294 patients with axillary node-positive primary breast cancer of STAGE I-IIIa were randomly assigned to either CEF [cyclophosphamide (CPA) 500 mg/m(2) i.v. days 1 and 8; epirubicin (EPI) 60 mg/m(2) i.v. day 1; and 5-fluorouracil (5-FU) 500 mg/m(2) i.v. days 1 and 8] or CMF [CPA 500 mg/m(2) i.v. days 1 and 8; methotrexate (MTX) 40 mg/m(2) i.v. days 1 and 8; and 5-FU 500 mg/m(2) i.v. days 1 and 8].
  • Both treatment regimens were comprised of six cycles at 4-week intervals.
  • Adverse drug reactions (ADRs) occurred more frequently in CEF.
  • The principal cause of the failure seems to be insufficient power, that is, the dose intensity (EPI: 60 mg/m(2)) set 10 years ago, when the trial began, was low, and the number of trial subjects was small because of the background of the times, which made the accumulation of cases extremely difficult.
  • However, the trial should be considered to be meaningful, as it was the first, formally conducted controlled trial on chemotherapy in Japan.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Papillary / drug therapy
  • [MeSH-minor] Adult. Axilla. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Japan. Lymphatic Metastasis. Methotrexate / administration & dosage. Middle Aged. Receptors, Estrogen / metabolism. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575284.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Yuyama Y, Yagihashi A, Hirata K, Ohmura T, Suzuki Y, Okamoto J, Yamada T, Okazaki Y, Watanabe Y, Okazaki A, Toda K, Okazaki M, Yajima T, Kameshima H, Araya J, Watanabe N: Neoadjuvant intra-arterial infusion chemotherapy combined with hormonal therapy for locally advanced breast cancer. Oncol Rep; 2000 Jul-Aug;7(4):797-801
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant intra-arterial infusion chemotherapy combined with hormonal therapy for locally advanced breast cancer.
  • To determine the efficacy of combined neoadjuvant intra-arterial infusion chemotherapy and hormonal therapy for treating locally advanced breast cancer, we compared the outcomes of patients with or without this therapy, and also assessed histologic response.
  • Ninety-four patients with locally advanced breast cancer (stage IIIa, 56; stage IIIb, 38).
  • Nineteen stage IIIa and 17 stage IIIb patients received intra-arterial plus hormonal therapy while 37 stage IIIa and 21 stage IIIb patients with similar ages and follow-up durations did not.
  • Five-year disease-free survival rates were 77.5% for intra-arterially treated and 33.0% for other patients in stage IIIa, and 70.5% for intra-arterially treated and 38.1% for other patients in stage IIIb.
  • Five-year overall survival rates were 94.4% for intra-arterially treated and 61.7% for other patients in stage IIIa, and 90.9% for intra-arterially treated and 56.3% for other patients in stage IIIb.
  • Ten-year overall survival rates in stage IIIb were 90.9% for treated and 22.5% for other group patents.
  • Good histologic response to intra-arterial therapy was seen in 75% of the primary tumors and 71% of involved lymph nodes.
  • Neoadjuvant intra-arterial therapy with hormonal therapy yielded better survival rates than no intra-arterial therapy or our previous intra-arterial regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Epirubicin / therapeutic use. Medroxyprogesterone Acetate / therapeutic use
  • [MeSH-minor] Administration, Oral. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10854547.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GREECE
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; C2QI4IOI2G / Medroxyprogesterone Acetate; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Murakami M, Kuroda Y, Nishimura S, Sano A, Okamoto Y, Taniguchi T, Nakajima T, Kobashi Y, Matsusue S: Intraarterial infusion chemotherapy and radiotherapy with or without surgery for patients with locally advanced or recurrent breast cancer. Am J Clin Oncol; 2001 Apr;24(2):185-91
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraarterial infusion chemotherapy and radiotherapy with or without surgery for patients with locally advanced or recurrent breast cancer.
  • We analyzed response, side effects, and local control rates of a multimodal treatment consisting of intraarterial infusion chemotherapy (IAIC) and radiotherapy with or without surgery for patients with locally advanced or recurred breast cancer.
  • Thirty-three patients, clinically diagnosed as stage IIB in 1, IIIA in 2, IIIB in 12, IV in 18, were treated from 1991 to 1998.
  • IAIC started as initial treatment up to three times maximum.
  • After IAIC, patients in primary cases underwent radical mastectomy or breast conservation surgery, after radiotherapy at a total dose of 50 Gy/25 fractions/5 weeks with a boost of 10 Gy.
  • Despite a high rate of residual positive margin (67%) or clinically residual carcinoma, local recurrence developed only in 2 patients (6%) and local control rates at 5 years were calculated as 89%.
  • IAIC was effective as an induction treatment and radiotherapy played a role of local control for patients with locally advanced or recurrent breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Infusions, Intra-Arterial. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11319296.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Shen ZZ, Liu GY, Su FX, He PQ, Yang MT, Shi JY, Sheng Y, Zou Q, Li YF: [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study]. Zhonghua Zhong Liu Za Zhi; 2005 Feb;27(2):126-8
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
  • OBJECTIVE: To investigate the clinical response, pathological complete response (pCR), tumor resection rate and safety of neoadjuvant chemotherapy with docetaxel and epirubicin (ET) for locally advanced breast cancer (LABC).
  • Twenty patients had clinical stage IIIa disease, 15 had stage IIIb disease and 5 stage IV patients who had ipsilateral sura-clavicular metastasis.
  • After 2 cycles of ET, a pilot clinical response evaluation was performed by investigators for each patient to decide if she should receive another 1-2 cycles of ET before surgery or radiation therapy.
  • CONCLUSION: Neo-adjuvant chemotherapy with a combination of docetaxel and epirubicin is effective and well tolerated by women with locally advanced breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Drug Administration Schedule. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Remission Induction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946557.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; P88XT4IS4D / Paclitaxel; ET protocol
  •  go-up   go-down


21. Brady EW: Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J; 2002 Mar-Apr;8(2):97-100
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer.
  • The purpose of this study was to evaluate the feasibility of sentinel lymph node mapping in patients undergoing neoadjuvant chemotherapy for breast carcinoma prior to lumpectomy or mastectomy and sentinel lymph node mapping followed by complete axillary dissection.
  • A retrospective analysis of 14 patients from February 1998 to July 2000 with stage I to stage IIIB breast cancer diagnosed by core biopsy underwent neoadjuvant chemotherapy (doxorubicin/cyclophosphamide) prior to definitive surgery, including lumpectomy or mastectomy and sentinel lymph node mapping, followed by full axillary dissection.
  • The single patient in whom a sentinel lymph node could not be identified had stage IIIA disease with extensive lymphatic tumor emboli.
  • Sentinel lymph node mapping is feasible in neoadjuvant chemotherapy breast cancer patients and can spare a significant number of patients the morbidity of full axillary dissection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / surgery. Lymph Nodes / pathology. Neoadjuvant Therapy. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Axilla. Biopsy, Needle. Female. Humans. Lymph Node Excision. Lymphatic Metastasis / pathology. Mastectomy. Mastectomy, Segmental. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11896755.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kuru B, Bozgul M: The impact of axillary lymph nodes removed in staging of node-positive breast carcinoma. Int J Radiat Oncol Biol Phys; 2006 Dec 1;66(5):1328-34
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of axillary lymph nodes removed in staging of node-positive breast carcinoma.
  • PURPOSE: Number of positive lymph nodes in the axilla and pathologic lymph node status (pN) have a great impact on staging according to the current American Joint Committee on Cancer staging system of breast carcinoma.
  • METHODS AND MATERIALS: The records of 798 consecutive invasive breast cancer patients with T1-3 tumors and positive axillary lymph nodes who underwent modified radical mastectomy between 1999 and 2005 in our hospital were reviewed.
  • Although the proportion of Stage IIA and IIB decreased, the proportion of Stage IIIA and IIIC increased in patients with >20 nodes removed compared with those with 1-20 nodes removed.
  • CONCLUSIONS: In patients with axillary node-positive breast carcinoma, staging is highly influenced by total number of removed nodes.
  • Levels I-III axillary dissection with more than 20 axillary lymph nodes removed could lead to more effective adjuvant chemotherapy and increases substantially the proportion of patients to receive radiotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Lymph Node Excision. Lymph Nodes / pathology. Neoplasm Staging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997505.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, Usuda J, Kato H: The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg; 2007 Apr;13(2):73-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.
  • Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancers, with patients having a poor prognosis.
  • Approximately one third of NSCLC patients present with early-stage disease in which potentially curative resection and multi-modality therapy.
  • Although adjuvant chemotherapy is the standard practice for patients with stages I-III breast and colorectal cancer, the therapeutic efficacy of adjuvant chemotherapy, following complete surgical resection of early stage NSCLC, has not been fully established.
  • Several prospective randomized trials for patients with early stage NSCLC (stages I-IIIA) have confirmed a survival benefit with cisplatin-based adjuvant chemotherapy, as demonstrated in the 1995 meta-analysis performed by the NSCLC Collaborative Group.
  • Studies from Japan have reported that adjuvant therapy with uracil-tegaful (UFT) afforded an improvement of 4% in the 5-year survival rate and a relative risk reduction of 26% in mortality at 5 years among patients with T1-2N0 (stage I) disease.
  • In particular, the Japan Lung Cancer Research Group has demonstrated an improvement in the 5-year survival rate of 11%, favoring chemotherapy with UFT in the subset of patients with T2N0 (stage IB) disease.
  • The Lung Adjuvant Cisplatin Evaluation (LACE), which was based on a pooled analysis of five randomized trials, has demonstrated that cisplatin-based adjuvant chemotherapy improved survival in patients with completely resected NSCLC.
  • This benefit depended on stage, being greatest in patients with stage II or IIIA disease.
  • This analysis has suggested that platinum-based adjuvant chemotherapy may have no benefit for patients with stage IA and only a marginal benefit for patients with stage IB.
  • Thus, the information available at the current time supports the administration of adjuvant chemotherapy for patients who have undergone complete resection of stages IB-IIIA NSCLC.
  • Further research is needed to define the role of adjuvant platinum-based chemotherapy and its use, in conjunction with chest radiotherapy as the treatment for patients with resected stages IB and IIIA NSCLC.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / mortality
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / therapeutic use. Carboplatin / therapeutic use. Chemotherapy, Adjuvant. Clinical Trials, Phase III as Topic. Humans. Paclitaxel / therapeutic use. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505412.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 18
  •  go-up   go-down


24. Gatek J, Dudesek B, Hnátek L, Vázan P, Cechácek M, Hradská K, Kotoc J, Musil T, Duben J: [Local recurrences after conservative surgery in breast carcinoma]. Klin Onkol; 2008;21(4):169-73
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local recurrences after conservative surgery in breast carcinoma].
  • BACKGROUND: Local recurrences in breast after conservative surgery are failure of primary therapy.
  • MATERIALS AND METHODS: Between 1.12.1998 and 30.06.2004, 143 patients with breast carcinoma were treated at Department of Surgery Atlas Hospital Zlin by conservative surgery.
  • All patients received radiotherapy and boost in breast.
  • Dose of the radiotherapy whole breast and cavity were 50 Gy, interval 5-6 weeks, daily 2Gy.
  • Brachytherapy received all patients, combination of chemotherapy and hormonal therapy were 56x, only chemotherapy 31x, only hormonal therapy 31x and without adjuvant therapy 25x.
  • Stage: 0 1x, I 58x, IIA 56x, IIB 24x, IIIA 4x.
  • Local recurrences in breast were 5x, (3.49%), distant metastases 6x, (4.1%) and 3x (2.09%) appeared distant metastases and death at breast carcinoma without local recurrence.
  • Interval from the time of initial treatment to local recurrences was from 12 to 42 month.
  • Surgical treatment of local recurrences included mastectomy 4x and conservative surgery 1x.
  • CONCLUSION: Number of local recurrences is in correspondence with international guideline and results of modern multimodal therapy.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy, Segmental. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / radiotherapy. Carcinoma, Ductal, Breast / secondary. Carcinoma, Ductal, Breast / surgery. Combined Modality Therapy. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102224.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


25. Brancato G, Gandolfo L, Privitera A, Donati M, Amodeo C: Locally advanced breast cancer in the elderly: a major challenge requiring effective and appropriate treatment. Tumori; 2002 Nov-Dec;88(6):467-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced breast cancer in the elderly: a major challenge requiring effective and appropriate treatment.
  • AIMS AND BACKGROUND: Breast cancer is the most common tumor in women.
  • As the population above 65 years increases, breast cancer will be a more substantial problem for elderly patients.
  • This work reports our experience in the management of stage III and IV locally advanced breast cancer.
  • METHODS: Nineteen patients over 65 years of age (mean, 70.3 years) with stage III and IV breast cancers, treated between 1990 and 2000, are considered.
  • RESULTS: Nine patients had stage IIIA breast cancer, 7 stage IIIB and 3 stage IV.
  • Patients at stage IIIB and 1 patient at stage IV with T4 tumor received neo-adjuvant chemotherapy.
  • Sixteen patients were given tamoxifen and 10 patients adjuvant chemotherapy.
  • In 8 patients with stage IlIl disease, metastasis developed.
  • Of the patients at stage IIIA, 6 were free from disease (one died from unrelated causes) and 3 had recurrent disease (2 died).
  • Of the patients at stage IIIB, 2 are disease free and 5 had recurrent disease and died.
  • Of the patients at stage IV, only one is alive.
  • CONCLUSIONS: Stage and individual characteristics of elderly women influence management.
  • Patients should be managed adequately since most of them are fit enough to undergo treatment.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / therapy
  • [MeSH-minor] Age Factors. Aged. Chemotherapy, Adjuvant. Female. Humans. Mastectomy / methods. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12597139.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM: Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol; 2004 Oct 15;22(20):4067-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy.
  • PURPOSE: To determine long-term event-free (EFS) and overall survival (OS) for patients with stage III breast cancer treated with combined-modality therapy.
  • PATIENTS AND METHODS: Between 1980 and 1988, 107 patients with stage III breast cancer were prospectively enrolled for study at the National Cancer Institute and stratified by whether or not they had features of inflammatory breast cancer (IBC).
  • Patients with pathologic complete response received definitive radiotherapy to the breast and axilla, whereas patients with residual disease underwent mastectomy, lymph node dissection, and radiotherapy.
  • All patients underwent six additional cycles of adjuvant chemotherapy.
  • RESULTS: OS and EFS were obtained with a median live patient follow-up time of 16.8 years.
  • The 46 IBC patients had a median OS of 3.8 years and EFS of 2.3 years, compared with 12.2 and 9.0 years, respectively, in stage IIIA breast cancer patients.
  • Fifteen-year OS survival was 20% for IBC versus 50% for stage IIIA patients and 23% for stage IIIB non-IBC.
  • Pathologic response was not associated with improved survival for stage IIIA or IBC patients.
  • CONCLUSION: Fifteen-year follow-up of stage IIIA and inflammatory breast cancer is rarely reported; IBC patients have a poor long-term outlook.
  • [MeSH-major] Breast Neoplasms / therapy. Combined Modality Therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Inflammation. Mastectomy. Middle Aged. Neoadjuvant Therapy. Survival Rate


27. Favret AM, Carlson RW, Goffinet DR, Jeffrey SS, Dirbas FM, Stockdale FE: Locally advanced breast cancer: is surgery necessary? Breast J; 2001 Mar-Apr;7(2):131-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced breast cancer: is surgery necessary?
  • A retrospective analysis of the treatment of locally advanced breast cancer (LABC) was undertaken at Stanford Medical Center to assess the outcome of patients who did not undergo surgical removal of their tumors.
  • Between 1981 and 1998, 64 patients with locally advanced breast cancer were treated with induction chemotherapy, radiation with or without breast surgery, and additional chemotherapy.
  • Sixty-two (97%) patients received cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction chemotherapy.
  • Induction chemotherapy was followed by local radiotherapy in 59 (92%) patients.
  • Based on the clinical response to chemotherapy and patient preference, 44 (69%) patients received no local breast surgery.
  • Radiotherapy was followed by an additional, non-doxorubicin-containing chemotherapy in all patients.
  • Of the 65 locally advanced breast cancers in 64 patients, 26 (41%) were stage IIIA, 35 (55%) were stage IIIB, and 4 (6%) were stage IV (supraclavicular lymph nodes only).
  • Response to induction chemotherapy was seen in 59 patients (92%), with 29 (45%) achieving a complete clinical response and 30 (47%) a partial clinical response.
  • These data indicate that the routine inclusion of breast surgery in a combined modality treatment program for LABC does not appear necessary for the majority of patients who experience a response to induction chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / radiotherapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Mastectomy / utilization. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome. Unnecessary Procedures

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11328324.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; CAF protocol
  •  go-up   go-down


28. Allen SM, Shah AC, Nezu AM, Nezu CM, Ciambrone D, Hogan J, Mor V: A problem-solving approach to stress reduction among younger women with breast carcinoma: a randomized controlled trial. Cancer; 2002 Jun 15;94(12):3089-100
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A problem-solving approach to stress reduction among younger women with breast carcinoma: a randomized controlled trial.
  • BACKGROUND: Previous research indicates that younger women (i.e., <or= 50) with breast carcinoma experience greater emotional distress than older women (i.e., > 50) and that coping style is significantly related to the psychosocial adjustment of women with this disease.
  • The purpose of this study was to evaluate through a randomized controlled trial the effectiveness of a problem-solving training intervention designed to empower women with breast carcinoma to cope with a range of difficulties when diagnosed in mid-life.
  • METHODS: The study population consisted of women aged 50 years or younger who had no prior history of breast carcinoma, were diagnosed with Stage I-IIIA tumors, and for whom a first course of chemotherapy had been initiated recently.
  • CONCLUSIONS: We conclude that this problem-solving therapy-based home care training intervention is an effective method of helping the majority of women with breast carcinoma to reduce the stresses associated with the diagnosis and treatment of cancer in mid-life.
  • [MeSH-major] Breast Neoplasms / psychology. Stress, Psychological / prevention & control

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stress.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12115339.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA64703
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


29. Li XQ, Li J, Shi SB, Chen P, Yu LC, Bao QL: Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. Int J Biol Markers; 2009 Oct-Dec;24(4):230-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy.
  • The development of resistance to chemotherapy is one of the major obstacles in the treatment of non-small cell lung cancer (NSCLC).
  • The purpose of this study was to investigate the prognostic value of multidrug resistance protein 1 (MRP1), breast cancer resistance protein (BCRP), lung resistance-related protein (LRP), and excision repair cross-complementing 1 (ERCC1) in NSCLC patients receiving cisplatin-based adjuvant chemotherapy (cisplatin plus vinorelbine or gemcitabine) after tumor resection.
  • We used semiquantitative reverse-transcription polymerase chain reaction to detect the expression of MRP1, BCRP, LRP and ERCC1 mRNA in surgical resection specimens of 60 patients with stage IB through IIIA NSCLC.
  • The results showed that stage IIIA (p=0.011), N1 and N2 status (p=0.008), high expression of MRP1 (p=0.034) and LRP (p=0.018) were associated with shorter TFS.
  • Stage IIIA (p=0.0105), N1 and N2 status (p=0.009), high expression of MRP1 (p=0.021) and ERCC1 (p=0.012) were related to a shorter overall survival.
  • Cox multivariate analyses revealed that early stage (p=0.013 and p=0.024), negative lymph node status (p=0.006 and p=0.011), and low MRP1 expression (p=0.022 and p=0.035) were independent predictors of favorable TFS and overall survival, respectively.
  • [MeSH-major] ATP-Binding Cassette Transporters / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / metabolism. DNA-Binding Proteins / genetics. Endonucleases / genetics. Lung Neoplasms / metabolism. Multidrug Resistance-Associated Proteins / genetics. Neoplasm Proteins / genetics. Vault Ribonucleoprotein Particles / genetics
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prognosis. Proportional Hazards Models. RNA, Messenger / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858899 for PMID:20082278 [PharmGKB] .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20082278.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / DNA-Binding Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; Q20Q21Q62J / Cisplatin; Y49M64GZ4Q / multidrug resistance-associated protein 1
  •  go-up   go-down


30. Irwin ML, Crumley D, McTiernan A, Bernstein L, Baumgartner R, Gilliland FD, Kriska A, Ballard-Barbash R: Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer; 2003 Apr 1;97(7):1746-57
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study.
  • BACKGROUND: Increased body weight at the time patients are diagnosed with breast carcinoma has been associated with an increased risk of recurrence and reduced survival.
  • In this population-based study, the authors investigated whether PA levels after diagnosis declined from prediagnosis levels and whether any changes in PA varied by disease stage, adjuvant treatment, patient age, or body mass index (BMI) in 812 patients with incident breast carcinoma (from in situ to Stage IIIa).
  • METHODS: Types of sports and household activities and their frequency and duration for the year prior to diagnosis and for the month prior to the interview (i.e., 4-12 months postdiagnosis) were assessed during a baseline interview.
  • Greater decreases in sports PA were observed among women who were treated with radiation and chemotherapy (50% decrease) compared with women who underwent surgery only (24% decrease) or who were treated with radiation only (23%; (P < 0.05).
  • CONCLUSIONS: PA levels were reduced significantly after patients were diagnosed with breast carcinoma.
  • Randomized, controlled trials are needed to evaluate how PA may improve the prognosis for patients with breast carcinoma.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11227
  • [Cites] Cancer Pract. 2000 Jan-Feb;8(1):16-24 [10732535.001]
  • [Cites] Nutrition. 2000 Mar;16(3):179-88 [10705072.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):47-59 [11227925.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2381-9 [11331316.001]
  • [Cites] Oncol Nurs Forum. 2001 May;28(4):675-84 [11383182.001]
  • [Cites] Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504 [10993420.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 17;94(8):606-16 [11959894.001]
  • [Cites] Am J Epidemiol. 1989 Jun;129(6):1120-31 [2729251.001]
  • [Cites] Int J Epidemiol. 1991 Mar;20(1):151-6 [2066214.001]
  • [Cites] Epidemiol Rev. 1993;15(1):48-65 [8405212.001]
  • [Cites] Oncol Nurs Forum. 1994 Jun;21(5):899-907; discussion 908 [7937251.001]
  • [Cites] J Am Diet Assoc. 1999 Oct;99(10):1212-21 [10524383.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):120-9 [10458225.001]
  • [Cites] Eur J Clin Nutr. 1994 Jun;48(6):408-15 [7925223.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1128-43 [11844838.001]
  • [Cites] JAMA. 1995 Feb 1;273(5):402-7 [7823386.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 6;87(17):1297-302 [7658481.001]
  • [Cites] Am J Clin Nutr. 1997 May;65(5):1495-501 [9129482.001]
  • [Cites] J Am Diet Assoc. 1997 May;97(5):519-26, 529; quiz 527-8 [9145091.001]
  • [Cites] J Altern Complement Med. 1997 Fall;3(3):215-26 [9430325.001]
  • [Cites] Breast Cancer Res Treat. 1998 Mar;48(1):53-64 [9541189.001]
  • [Cites] Obes Res. 1998 Sep;6 Suppl 2:51S-209S [9813653.001]
  • [Cites] Cancer. 1999 May 15;85(10):2273-7 [10326708.001]
  • (PMID = 12655532.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / PC / PC035138-22; United States / NCI NIH HHS / CA / T32 CA09661; United States / NCRR NIH HHS / RR / M01-RR-00037; United States / NCI NIH HHS / CN / N01-CN-75036-20; United States / NCRR NIH HHS / RR / M01 RR000037; United States / NCI NIH HHS / PC / N01 PC035138-22; United States / NCI NIH HHS / CN / N01 CN005228; United States / NCI NIH HHS / CN / N01-CN-05228; United States / NCI NIH HHS / CA / T32 CA009661
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS250939; NLM/ PMC3034406
  •  go-up   go-down


31. Downes KJ, Glatt BS, Kanchwala SK, Mick R, Fraker DL, Fox KR, Solin LJ, Bucky LP, Czerniecki BJ: Skin-sparing mastectomy and immediate reconstruction is an acceptable treatment option for patients with high-risk breast carcinoma. Cancer; 2005 Mar 1;103(5):906-13
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin-sparing mastectomy and immediate reconstruction is an acceptable treatment option for patients with high-risk breast carcinoma.
  • BACKGROUND: Skin-sparing mastectomy (SSM) followed by immediate reconstruction is an effective treatment option for patients with early-stage breast carcinoma, but its use in patients with more advanced disease is controversial.
  • METHODS: A retrospective review was performed that included 38 consecutive patients with high-risk breast carcinoma who underwent SSM and immediate reconstruction (between July 1996 and January 2002).
  • Tumor characteristics, type of reconstruction, margin status, timing of adjuvant therapy, postoperative complications, and incidence of recurrence were evaluated.
  • RESULTS: High-risk patients (Stage IIA [n=4 patients] Stage IIB [n=23 patients] Stage IIIA [n=8 patients] and Stage IIIB [n=3 patients]) underwent immediate reconstruction after SSM with the use of a transverse rectus abdominis myocutaneous flap (n=31 patients), a latissimus dorsi myocutaneous flap plus an implant (n=3 patients), or tissue expanders with subsequent implant placement (n=4 patients).
  • The median follow-up was 52.9 months (range, 27.5-92.0 months), and the median time to recurrence has not yet been reached at the time of last follow-up.
  • The median interval from surgery to the initiation of postoperative adjuvant therapy was 38 days (range, 25-238 days).
  • CONCLUSIONS: SSM with immediate reconstruction appeared to be an oncologically safe treatment option for high-risk patients with advanced stages of breast carcinoma.
  • In addition to the aesthetic and psychological benefits of performing SSM with immediate reconstruction, local recurrence rates and disease-free survival were favorable when combined with the use of radiation therapy and adjuvant chemotherapy, as indicated.
  • [MeSH-major] Breast Implants. Breast Neoplasms / surgery. Carcinoma / surgery. Mastectomy / methods. Surgical Flaps
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Postoperative Complications. Rectus Abdominis. Retrospective Studies. Risk. Time Factors


32. Li J, Li ZN, Yu LC, Bao QL, Wu JR, Shi SB, Li XQ: Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer; 2010 Jul;69(1):116-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy.
  • PURPOSE: The aim of this study was to investigate prognostic value of multidrug resistance protein 1 (MRP1), breast cancer resistance protein (BCRP), lung resistance-related protein (LRP) and excision repair cross-complementing 1 (ERCC1) in patients with locally advanced non-small cell lung cancer (NSCLC) who received neoadjuvant cisplatin-based chemotherapy.
  • METHODS: Transbronchial biopsy (TBB) specimens from 46 patients with stage IIIA (N(2)) NSCLC were collected to determine the expression level of MRP1, BCRP, LRP and ERCC1 mRNA by semiquantitative RT-PCR.
  • The expression level of each gene was analyzed in relation to histopathologic response to chemotherapy, and tumor-free survival (TFS) and overall survival.
  • CONCLUSION: Assessment of MRP1 and LRP mRNA expression in TBB specimens may predict histopathologic response and survival in locally advanced NSCLC patients who received neoadjuvant cisplatin-based chemotherapy.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Carcinoma, Non-Small-Cell Lung / diagnosis. DNA-Binding Proteins / metabolism. Endonucleases / metabolism. Lung Neoplasms / diagnosis. Multidrug Resistance-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19875192.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / DNA-Binding Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; Q20Q21Q62J / Cisplatin; Y49M64GZ4Q / multidrug resistance-associated protein 1
  •  go-up   go-down


33. Somlo G, Doroshow JH, Synold T, Longmate J, Reardon D, Chow W, Forman SJ, Leong LA, Margolin KA, Morgan RJ Jr, Raschko JW, Shibata SI, Tetef ML, Yen Y, Kogut N, Schriber J, Alvarnas J: High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome. Br J Cancer; 2001 Jun 15;84(12):1591-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome.
  • Between October 1995 and June 1998, 63 patients with high-risk primary [stage II with >or= 10 axillary nodes involved, stage IIIA or stage IIIB inflammatory carcinoma (n = 53)] or with stage IV responsive breast cancer (n = 10) received paclitaxel 150-775 mg/m(2)infused over 24 hours, doxorubicin 165 mg/m(2)as a continuous infusion over 96 hours, and cyclophosphamide 100 mg kg(-1).
  • There were no treatment-related deaths.
  • Kaplan-Meier estimates of 30-month event-free and overall survival for patients with primary breast carcinoma are 65% (95% CI; 51-83%) and 77% (95% CI; 64-93%).

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Cancer Research Campaign.
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):225-33 [10655439.001]
  • [Cites] Hematol Cell Ther. 1999 Apr;41(2):71-4 [10344555.001]
  • [Cites] Acta Oncol. 2000;39(1):47-52 [10752653.001]
  • [Cites] Ther Drug Monit. 1985;7(4):455-60 [4082243.001]
  • [Cites] Br J Cancer. 1989 Jul;60(1):121-5 [2478178.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1824-30 [2511276.001]
  • [Cites] J Pharm Biomed Anal. 1990;8(2):159-64 [1982732.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1261-7 [1675263.001]
  • [Cites] J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805 [1683908.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1132-43 [8501500.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1943-51 [7691998.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):532-8 [7907130.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1253-9 [8080512.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1678-85 [7512436.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1621-9 [7913721.001]
  • [Cites] Semin Oncol. 1994 Oct;21(5 Suppl 8):19-23 [7939757.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):180-90 [7799018.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1463-72 [8622060.001]
  • [Cites] J Infus Chemother. 1996 Spring;6(2):69-73 [8809652.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1521-8 [9057632.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1870-9 [9164197.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1906-15 [9164201.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2882-93 [9256132.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1689-95 [9676843.001]
  • [Cites] Lancet. 1998 Aug 15;352(9127):515-21 [9716055.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):847-54 [9816240.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1008-14 [9849448.001]
  • [Cites] N Engl J Med. 2000 Apr 13;342(15):1069-76 [10760307.001]
  • (PMID = 11401310.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA33572; United States / NCI NIH HHS / CA / CA62505
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2363687
  •  go-up   go-down


34. Gelber RP, McCarthy EP, Davis JW, Seto TB: Ethnic disparities in breast cancer management among Asian Americans and Pacific Islanders. Ann Surg Oncol; 2006 Jul;13(7):977-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnic disparities in breast cancer management among Asian Americans and Pacific Islanders.
  • BACKGROUND: Little is known about breast cancer management among Asian Americans and Pacific Islanders (AAPI).
  • METHODS: We performed a retrospective analysis of 2030 women (935 Japanese, 144 Chinese, 235 Filipino, 293 Hawaiian, and 423 white; mean age +/- SD, 59 +/- 13 years) with a diagnosis of early breast cancer (stages I, II, and IIIA) in Hawaii from 1995 to 2001.
  • We evaluated (1) breast-conserving surgery (BCS);.
  • (2) radiotherapy after BCS; and (3) chemotherapy for node-positive disease.
  • We used logistic regression to examine the association between AAPI ethnicity and treatment, adjusting for age, year, rural residence, tumor size, grade, nodal status, receptor status, prior cancer, comorbidity index, health plan type, and income.
  • RESULTS: Overall, 60.3% of women had stage I disease, 36.8% had stage II, and 2.9% had stage IIIA.
  • Of those with nodal involvement (n = 521), 82.7% received chemotherapy.
  • AAPI women were as likely as white women to receive adjuvant chemotherapy for nodal spread.
  • CONCLUSIONS: We found disparities in the management of early-stage breast cancer among AAPI women, particularly among Japanese and Filipinos.
  • [MeSH-major] Asian Americans / statistics & numerical data. Breast Neoplasms / ethnology. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / ethnology. Carcinoma, Ductal, Breast / therapy. Oceanic Ancestry Group / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asia / ethnology. Combined Modality Therapy. Female. Humans. Mastectomy, Segmental / trends. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. United States


35. Mitsuyama S, Anan K, Ono M: [A case of recurrent breast cancer successfully treated with capecitabine monotherapy]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1153-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent breast cancer successfully treated with capecitabine monotherapy].
  • A 51-year-old woman underwent pectoralis-preserving mastectomy for right breast cancer (squamous cell cancer, f, T1c, ly0, v0, N2 (18/33), p53 (3+), HER2 (2+), ER (-), PgR (-), T1cN2M0 (Stage IIIA) in March 2001, and received systemic chemotherapy using doxorubicin combined with cyclophosphamide, followed by paclitaxel.
  • After chemotherapy, radiotherapy was added to the chest wall, supraclavicular and parasternal regions.
  • Systemic therapy using docetaxel, and hepatic artery infusion therapy with epirubicin following docetaxel, failed.
  • This therapy is being continued (18 cycles), and no serious side effects have been encountered.
  • Capecitabine monotherapy is safe and very useful for recurrent breast cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. Deoxycytidine / analogs & derivatives. Neoplasm Recurrence, Local
  • [MeSH-minor] Capecitabine. Female. Fluorouracil / analogs & derivatives. Humans. Liver Neoplasms / secondary. Mastectomy, Modified Radical. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121919.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


36. Bollet MA, Savignoni A, Pierga JY, Lae M, Fourchotte V, Kirova YM, Dendale R, Campana F, Sigal-Zafrani B, Salmon R, Fourquet A, Vincent-Salomon A: High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies. Br J Cancer; 2008 Feb 26;98(4):734-41
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies.
  • The literature reports low rates of breast conservation after neoadjuvant chemotherapy for operable breast cancers not amenable to initial breast-conserving surgery.
  • This study aims to compare the outcome of lobular vs ductal carcinomas after neoadjuvant chemotherapy.
  • Between 1989 and 1999, 750 patients with clinical stage II/IIIA ductal (672) or lobular (78) invasive breast carcinomas were treated at the Institut Curie with primary anthracycline-based polychemotherapy followed by either breast conservation (surgery and/or radiotherapy) or mastectomy.
  • Clinical response to primary chemotherapy was significantly worse for lobular than for ductal carcinomas (47 vs 60%; P=0.04), but only histological grade remained predictive in multivariate analysis.
  • Breast conservation was high for both ductal and lobular carcinomas (65 and 54%; P=0.07), due, in part, to the use of radiotherapy, either exclusive or preoperative, for respectively 26 and 40% of patients.
  • The lobular type had no adverse effect, neither on locoregional control nor on overall survival, even in the group of patients treated with breast conservation.
  • [MeSH-major] Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / therapy. Mastectomy, Segmental. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):27-33 [9495354.001]
  • [Cites] Eur J Surg Oncol. 2008 Feb;34(2):135-42 [17574805.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):677-85 [10524422.001]
  • [Cites] Br J Cancer. 1957 Sep;11(3):359-77 [13499785.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):41-8 [15625359.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):188-94 [15687361.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1169-77 [15718313.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1348-54 [15817336.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2996-3000 [15860855.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jun;184(6):1774-81 [15908529.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1274-82 [16029782.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5678-85 [16115903.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7265-77 [16145055.001]
  • [Cites] J Radiol. 2005 Sep;86(9 Pt 1):1027-34 [16224343.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8331-9 [16293864.001]
  • [Cites] Breast Cancer Res Treat. 1999 Nov;58(2):151-6 [10674880.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1220-9 [10715291.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):602-11 [11157009.001]
  • [Cites] J Magn Reson Imaging. 2001 Jun;13(6):821-9 [11382939.001]
  • [Cites] Breast Cancer Res. 2002;4(3):R3 [12052255.001]
  • [Cites] Ann Surg. 2003 Jan;237(1):26-34 [12496527.001]
  • [Cites] Eur J Cancer. 2003 May;39(8):1089-96 [12736108.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4540-5 [14673041.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):342-51 [14746851.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1349-60 [15054453.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1502-8 [15196533.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jul;86(1):31-7 [15218359.001]
  • [Cites] AJR Am J Roentgenol. 2004 Oct;183(4):1159-68 [15385323.001]
  • [Cites] Bull Cancer. 1987;74(6):641-6 [3435789.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):325-9 [1648043.001]
  • [Cites] Ann N Y Acad Sci. 1993 Nov 30;698:193-203 [8279757.001]
  • [Cites] Radiology. 1994 Jun;191(3):625-31 [8184038.001]
  • [Cites] Eur J Cancer. 1994;30A(5):645-52 [8080680.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):113-20 [8630916.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2087-106 [16360786.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1228-33 [16740599.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14):2286-95 [16893641.001]
  • [Cites] Lancet Oncol. 2007 Jan;8(1):55-62 [17196511.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):341-51 [17133270.001]
  • [Cites] Clin Imaging. 2007 May-Jun;31(3):155-61 [17449375.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;104(1):109-14 [17061042.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):13-8 [17449193.001]
  • [Cites] J Surg Oncol. 2007 Nov 1;96(6):474-80 [17640031.001]
  • [Cites] Rontgenpraxis. 1998;51(7):235-42 [9793406.001]
  • (PMID = 18253121.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2259192
  •  go-up   go-down


37. Al-Tweigeri TA, Ajarim DS, Alsayed AA, Rahal MM, Alshabanah MO, Tulbah AM, Al-Malik OA, Fatani DM, El-Husseiny GA, Elkum NB, Ezzat AA: Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer. Med Oncol; 2010 Sep;27(3):571-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.
  • The objective of this study is to evaluate the efficacy and safety profile of the doxorubicin followed by cisplatin/docetaxel as primary chemotherapy for patients with locally advanced breast cancer (LABC).
  • For this evaluation, 59 patients with LABC (T2-T4, N0-N2, M0) received three cycles of doxorubicin, followed by three cycles of cisplatin/docetaxel and followed by definitive surgery and locoregional radiotherapy with or without tamoxifen.
  • The primary end point was pathologic complete response (pCR) in breast and axilla.
  • Fifty-nine patients were evaluable for analysis: median age: 41 years, premenopausal: 68%, median tumor size: 6.0 cm (4-10), Stage IIB: 32% and IIIA/IIIB: 68%, both ER/PR positive: 53%, Her2/neu (3+) by IHC staining: 29%.
  • Breast conserving surgery was performed in 44%, and MRM in 56%.
  • pCR in the breast was 30.5%, in axilla was 37%, and pCR in both breast and axilla was 24%.
  • The DFS and OS of patients who achieved complete pathologic response in breast and axilla were 78 and 100%, respectively, while 14 patients relapsed of which 46% were Her2 positive.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma / drug therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Estrogens. Female. Genes, erbB-2. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Mastectomy, Modified Radical. Mastectomy, Segmental. Middle Aged. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / pathology. Progesterone. Prospective Studies. Radiotherapy, Adjuvant. Tamoxifen / administration & dosage. Taxoids / administration & dosage. Taxoids / adverse effects. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2001 Feb;28(1 Suppl 2):10-4 [11284619.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2676-85 [15837982.001]
  • [Cites] Ann Oncol. 1997 Jul;8(7):663-7 [9296219.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1189-200 [17701939.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jul;98(1):57-61 [16752226.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2019-27 [16606972.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):56-63 [15598939.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1456-66 [11896092.001]
  • [Cites] Breast Cancer Res Treat. 2000 Aug;62(3):237-44 [11072788.001]
  • [Cites] Br J Surg. 1999 May;86(5):665-8 [10361191.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1005-12 [17047649.001]
  • [Cites] Clin Breast Cancer. 2005 Jun;6(2):163-8 [16001995.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):118S-124S [11560986.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):106S-111S [11560984.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4224-37 [11709566.001]
  • [Cites] Oncology. 2007;72(1-2):17-26 [17998786.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):968-74 [14997191.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1172-6 [17434897.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2483-93 [9215816.001]
  • [Cites] Semin Oncol. 2001 Feb;28(1 Suppl 3):28-37 [11301372.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):814-9 [18258991.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):286-92 [9888470.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2600-8 [12829681.001]
  • [Cites] Breast Cancer Res Treat. 1995 Apr;34(1):63-9 [7749161.001]
  • [Cites] Ann Oncol. 2004 May;15(5):751-8 [15111342.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):843-50 [12610183.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):778-85 [18258986.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2988-95 [15860854.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4911-6 [17214361.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):2012-8 [17513805.001]
  • [Cites] Clin Breast Cancer. 2004 Dec;5(5):371-6 [15585076.001]
  • (PMID = 19526202.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 15H5577CQD / docetaxel; 4G7DS2Q64Y / Progesterone; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


38. Paciucci PA, Raptis G, Bleiweiss I, Weltz C, Lehrer D, Gurry R: Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer. Anticancer Drugs; 2002 Sep;13(8):791-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer.
  • Neo-adjuvant, dose-dense docetaxel, 100 mg/m(2) every 2 weeks x 4 cycles, was administered to 12 patients with locally advance breast cancer (LABC) (10 stage IIIa and three stage IIIb).
  • Filgrastim [granulocyte colony stimulating factor (G-CSF)] was started 1 day after chemotherapy and was given for 6 days.
  • The median age was 45 (range 34-73) and pre-treatment pathology revealed poorly differentiated infiltrating duct carcinoma in 11 and infiltrating lobular cancer in one, with positive ER/PR status in five.
  • Three patients (of whom two with stage IIIb) had progressive disease and went on to receive neo-adjuvant therapy with AC.
  • There were two instances of grade 3 extra-hematologic toxicity: one patient had severe pain and one had treatment-related fatigue.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Granulocyte Colony-Stimulating Factor / administration & dosage. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Aged. Female. Filgrastim. Humans. Middle Aged. Neoadjuvant Therapy. Recombinant Proteins

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12394262.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 0 / Taxoids; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


39. Thatai LC, Vishnubhotla P, Biernat L, Flaherty L, LoRusso P, Simon M, Stephens D, Vereeke K, Abrams J, Bouwman D, Philip PA: A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancer. Am J Clin Oncol; 2006 Oct;29(5):484-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancer.
  • OBJECTIVE: The primary aim of this study was to estimate the rate of clinical and pathologic response to preoperative docetaxel, doxorubicin, and infusional 5-fluorouracil in patients with locally advanced breast cancer.
  • PATIENTS AND METHODS: Thirty-nine patients (median age 49 years) with histologically confirmed locally advanced breast cancer (stage IIIA or IIIB) were studied.
  • Patients received 4 courses of chemotherapy with docetaxel (75 mg/m2 iv over 1 hour), doxorubicin (50 mg/m2 iv bolus), and 5-fluorouracil (300 mg/m2/d as continuous iv infusion on days 1-5).
  • Treatment cycles were repeated every 21 days.
  • Definitive surgery was performed after the completion of 4 cycles of therapy.
  • Pathologic complete response was defined as the absence of invasive cancer in both the breast and ipsilateral axillary lymph nodes.
  • Thirteen patients (33%) developed neutropenic fever.
  • Fifty-three percent of the patients were hospitalized for treatment related complications.
  • No cardiotoxicity or treatment related deaths were observed.
  • CONCLUSIONS: Triple cytotoxic therapy based on concurrent doxorubicin and docetaxel with infusional 5-flourouracil (5-FU) does not appear to significantly improve the pathologic response in patients with locally advanced breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Doxorubicin / administration & dosage. Female. Filgrastim. Fluorouracil / administration & dosage. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Infusions, Intravenous. Middle Aged. Neoadjuvant Therapy. Recombinant Proteins. Survival Analysis. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17023784.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2P30-CA22-453-23
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Taxoids; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; PVI5M0M1GW / Filgrastim; U3P01618RT / Fluorouracil
  •  go-up   go-down


40. Katsuta E, Ohkubo T, Someno Y, Saguchi M, Aoyagi H, Takahata T, Hasegawa K, Hamada S, Kaneko J, Maejima S: [A long-term survival case of local recurrence of breast cancer treated with combined modality therapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2760-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survival case of local recurrence of breast cancer treated with combined modality therapy].
  • In 1997, the patient underwent pectoral muscle-preserving mastectomy and axillary/subclavicular lymph node dissection for the treatment of right breast cancer.
  • Histological diagnosis was invasive ductal carcinoma (T2, N2, M0, Stage IIIA).
  • She received a combination therapy with TAM and UFT for 5 years postoperatively.
  • Because tumor recurrence occurred in right axillary lymph nodes in the 9th postoperative year, the patient underwent resection of these lymph nodes followed by 6 cycles of AC-based chemotherapy.
  • Multiple lung metastases occurred in the 10th postoperative year, and then, the patient received 8 cycles of DOC-based chemotherapy.
  • In the 11th postoperative year, a mass appeared again in the right axilla, and 6 cycles of capecitabine-based chemotherapy was administered.
  • Six cycles of combined trastuzumab+PTX therapy were administered.
  • The patient is scheduled to receive a postoperative radiotherapy, followed by resumption of chemotherapy.
  • [MeSH-major] Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Mastectomy. Neoplasm Recurrence, Local. Paclitaxel / administration & dosage. Tamoxifen / administration & dosage. Taxoids / administration & dosage. Tegafur / administration & dosage. Trastuzumab. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224704.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 56HH86ZVCT / Uracil; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel; 1-UFT protocol
  •  go-up   go-down


41. De Cesare A, Burza A, Fiori E, Bononi M, Volpino P, Leone G, Crocetti A, Cangemi V: Assessment of surgical treatment in elderly patients with breast cancer. Tumori; 2008 May-Jun;94(3):314-9
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of surgical treatment in elderly patients with breast cancer.
  • AIMS AND BACKGROUND: The incidence of breast cancer increases with advancing age and in clinical practice approximately 50% of new cases occur in women over the age of 65 years.
  • Although breast cancer in elderly patients presents more favorable biological characteristics than similar-stage cancer in younger women, disease control still remains uncertain and is becoming a major health problem.
  • PATIENTS AND METHODS: Between 1984 and 2006, 133 patients aged over 65 with operable breast cancer underwent surgical treatment.
  • Patients with ductal or lobular carcinoma in situ, bilateral breast cancer or a previous malignancy were excluded.
  • Breast-conserving surgery was performed in patients with early breast cancer (T1, T2 < 2.5 cm), while most patients with advanced tumors (T2 >2.5 cm, T3, T4) were treated by modified radical mastectomy.
  • RESULTS: The pathological stage was I in 44, IIA in 54, IIB in 18, IIIA in 10 and IIIB in 7 patients.
  • Eighty-nine patients underwent adjuvant therapy (chemotherapy, hormonal therapy).
  • The overall mortality from breast cancer was 11%, whereas the cancer-unrelated mortality was 9%.
  • CONCLUSION: There is no evidence that breast cancer has a more favorable prognosis in the elderly and surgical procedures should be carried out as has been established in younger women.
  • However, in the absence of serious comorbid disease, they are able to withstand standard multimodal treatment options as well as do younger patients.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Mastectomy
  • [MeSH-minor] Aged. Aged, 80 and over. Axilla. Biomarkers, Tumor / analysis. Carcinoma in Situ / surgery. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / surgery. Disease Progression. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Neoplasm Staging. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705397.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


42. Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, Bryce C, Gelmon KA: Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol; 2007 Jan;18(1):45-51
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
  • BACKGROUND: Letrozole after 5 years of adjuvant tamoxifen results in a significant reduction in risk of recurrence from estrogen receptor (ER) positive breast cancer.
  • An individualized estimate of the risk of relapse and death after 5 years of tamoxifen could improve decisions regarding extended hormonal therapy.
  • METHODS: The British Columbia Breast Cancer Outcomes database was used to identify women aged 45 years or older at the time of diagnosis with early-stage (I-IIIA) breast cancer who received tamoxifen and were disease free 5 years after diagnosis.
  • Ten-year breast cancer event rates and mortality were calculated as well as annualized hazard rates of recurrence.
  • Annual breast cancer risk between years 6 and 10 was, respectively, 2.2%, 3.5% and 7.6% for N0, N1 and N2 disease and 2.6% and 4.5% for T1 and T2 breast cancer.
  • CONCLUSION: T and N stages predicted late relapse and death from breast cancer in a population-based cohort of postmenopausal women.
  • Risk estimates reported herein may be used to optimize decision making regarding adjuvant therapy after 5 years of tamoxifen.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030545.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 094ZI81Y45 / Tamoxifen; 7LKK855W8I / letrozole
  •  go-up   go-down


43. Fujii Y, Nakazawa K, Yoneto T, Shuzui Y: [A case of pericardial tamponade caused by recurrent breast cancer treated with intrapericardial and intrapleural infusion of cisplatin (CDDP)]. Gan To Kagaku Ryoho; 2006 Aug;33(8):1133-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pericardial tamponade caused by recurrent breast cancer treated with intrapericardial and intrapleural infusion of cisplatin (CDDP)].
  • Breast cancer rarely metastasizes to the pericardial cavity to cause cardiac tamponade.
  • We have recently experienced a case of pericardial tamponade due to recurrent breast cancer.
  • A 41-year-old woman who underwent modified radical mastectomy for a right breast cancer (T(1)N(3)M(0), Stage IIIA) 8 years and 8 months ago, was admitted for dyspnea and cough.
  • Based on cytodiagnosis of pericardial and pleural effusion, the diagnosis was pericardial and intrapleural metastases of the breast cancer.
  • After local chemotherapy with CDDP, systemic chemotherapy of CPT-11 was started.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Cardiac Tamponade / drug therapy. Cisplatin / administration & dosage. Pleural Effusion, Malignant / drug therapy
  • [MeSH-minor] Adult. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Infusions, Intralesional. Pericardial Effusion / etiology. Pericardiocentesis. Pleural Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912534.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


44. Kyparidou E, Athanasiadis A, Xydakis E, Papadakou M, Panagos G: Correlation of tissue transglutaminase expression on breast cancer tissue with time to relapse, overall survival, and clinical and molecular prognostic factors: a preliminary report. J BUON; 2005 Jan-Mar;10(1):81-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of tissue transglutaminase expression on breast cancer tissue with time to relapse, overall survival, and clinical and molecular prognostic factors: a preliminary report.
  • PURPOSE: To correlate tissue transglutaminase (TTG) expression with the expression of molecules with prognostic significance in breast cancer patients and with classical clinical parameters (disease stage, histological grade, overall survival (OS), relapse rate, disease progression and time to treatment failure-TTF).
  • PATIENTS AND METHODS: Paraffin-embedded tissue specimens from 68 breast cancer patients were studied retrospectively for TTG expression, estrogen (ER) and progesterone (PG) receptors, c-erbB-2, p53, Bcl-2, and Ki-67.
  • Histology was ductal carcinoma in 53 (inflammatory in 2 and mucinous in 1 of them), lobular in 13 and tubular in 2 cases.
  • Forty-six patients had early-stage disease (I - IIB) and 22 advanced (IIIA - IV).
  • CONCLUSION: Our data suggest that TTG is an independent favorable prognostic factor for survival, possibly enhancing the apoptotic effect of chemotherapy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17335136.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


45. Johnson BE, Rabin MS: Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer. Clin Cancer Res; 2005 Jul 1;11(13 Pt 2):5022s-5026s
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.
  • Adjuvant chemotherapy is the standard of therapy for some patients with stages I, II, and III breast and colon cancer.
  • The therapeutic efficacy of adjuvant chemotherapy following surgical resection of early stage non-small cell lung cancer (NSCLC) has been less clear.
  • A meta-analysis was reported in 1995 of patients who underwent surgical resection for early stage NSCLC and were then randomized to either observation or chemotherapy.
  • This meta-analysis showed a 13% reduction in the hazard ratio of death, leading to a 5% absolute improvement in survival 5 years after the start of adjuvant cisplatin-based chemotherapy treatment compared with observation only.
  • Six trials with > or =150 patients with early stage NSCLC (stages I-IIIA) on each arm have been reported in the last 2 years.
  • Four of the six trials show a survival advantage for the patients with early stage NSCLC treated with adjuvant chemotherapy compared with those who underwent observation.
  • The survival benefit in these four studies varies from a 4% to a 16% survival advantage at 4 to 5 years after the start of chemotherapy.
  • The hazard ratio of death for the patients treated with chemotherapy ranged from 0.61 to 0.86 compared with patients on observation.
  • Thus, the information available at the current time supports the administration of chemotherapy for patients with stages IB and II NSCLC.
  • Further research will be needed to define the role of adjuvant chemotherapy and its use in conjunction with chest radiotherapy for the treatment of patients with resected stages IA and IIIA NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Patient Selection. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Sex Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16000607.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 8
  •  go-up   go-down


46. Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M, Sasano H: Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res Treat; 2010 Apr;120(3):639-48
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
  • Aromatase inhibitors (AIs) are considered the gold standard for endocrine therapy of estrogen receptor (ER) positive postmenopausal breast cancer patients.
  • The therapy may enhance therapeutic response and stabilize disease but resistance and disease progression inevitably occur in the patients.
  • Therefore, in this study we evaluated effects of exemestane (EXE) upon the enzymes involved in intratumoral estrogen production including estrogen sulfatase (STS), 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1), and estrogen sulfotransferase (EST) and correlated the findings with therapeutic responses including Ki67 labeling index (Ki67).
  • 116 postmenopausal patients with invasive ductal carcinoma, stage II/IIIa, were enrolled in JFMC34-0601 clinical trials between March, 2006 and January, 2008.
  • Status of STS, EST, 17beta-HSD1, ER, progesterone receptor (PgR), human epidermal growth factor receptor type 2 (Her2), and Ki67 in pre- and post-specimens were evaluated.
  • Specimens examined before the therapy demonstrated following features; ER+ (100%), PgR+ (85.7%), and Her2+ (77.6%).
  • After treatment, the number of Ki67, PgR, and ER positive carcinoma cells demonstrated significant decrement in clinical response (CliR) and pathological response (PaR) groups.
  • Significant increment of 17beta-HSD1 and STS immunoreactivity was detected in all groups examined except for STS in PaR.
  • Alterations of Ki67 of carcinoma cells before and after therapy were subclassified into three groups according to its degrees.
  • Significant alterations of intratumoral enzymes, especially 17beta-HSD1 and STS, were correlated with Ki67 reduction after neoadjuvant EXE therapy.
  • This is the first study demonstrating significant increment of STS and 17beta-HSD1 following AI neoadjuvant therapy of postmenopausal ER positive breast carcinoma patients.
  • This increment may represent the compensatory response of breast carcinoma tissues to estrogen depletion.
  • [MeSH-major] Androstadienes / pharmacology. Antineoplastic Agents, Hormonal / pharmacology. Aromatase Inhibitors / pharmacology. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Estradiol Dehydrogenases / biosynthesis. Estrogens / metabolism. Neoplasm Proteins / biosynthesis. Neoplasms, Hormone-Dependent / drug therapy. Sulfatases / biosynthesis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Clinical Trials, Phase II as Topic / statistics & numerical data. Combined Modality Therapy. Female. Humans. Ki-67 Antigen / analysis. Mastectomy. Middle Aged. Multicenter Studies as Topic / statistics & numerical data. Neoadjuvant Therapy. Postmenopause. Receptors, Steroid / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. EXEMESTANE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20151319.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Androstadienes; 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Biomarkers, Tumor; 0 / Estrogens; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Receptors, Steroid; 107868-30-4 / exemestane; EC 1.1.1.62 / Estradiol Dehydrogenases; EC 1.1.1.62 / HSD17B1 protein, human; EC 3.1.6.- / Sulfatases; EC 3.1.6.- / estrogen sulfatase
  •  go-up   go-down


47. Le Chevalier T, Lynch T: Adjuvant treatment of lung cancer: current status and potential applications of new regimens. Lung Cancer; 2004 Dec;46 Suppl 2:S33-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment of lung cancer: current status and potential applications of new regimens.
  • Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of lung cancers diagnosed worldwide.
  • Surgical resection offers the best chance for cure for those patients diagnosed with early-stage disease; however, the vast majority of patients will eventually relapse.
  • Despite complete surgical resection, recurrences are likely due to undetectable microscopic disease at diagnosis, making these patients potential candidates for effective adjuvant therapy.
  • Postoperative radiation therapy may actually have a detrimental effect in patients with NO-N1 disease and has been shown to possibly prevent local recurrences in patients with N2 disease.
  • Although results from a large meta-analysis of data on adjuvant chemotherapy suggested an absolute benefit of 5% at 5 years from cisplatin-based chemotherapy, a rate similar to that seen in breast and colon cancers where adjuvant chemotherapy is a standard of care, the use of adjuvant therapy in NSCLC remained controversial.
  • In addition, results of the International Adjuvant Lung Cancer Trial (IALT), which compared adjuvant cisplatin-based chemotherapy to observation in patients with resected stage-I-IIIA NSCLC, suggested that adjuvant therapy had the potential to prevent a substantial number of deaths each year.
  • Two recently reported landmark studies have demonstrated the survival advantages of adjuvant therapy for patients with early-stage NSCLC.
  • As recent findings have established the value of adjuvant chemotherapy for early-stage NSCLC, agents such as docetaxel warrant rigorous evaluation in this setting.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Clinical Trials as Topic. Humans. Neoplasm Staging. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15698530.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 18
  •  go-up   go-down


48. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol; 2001 Dec;28(6):620-5
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials.
  • Recent studies have indicated that bone marrow angiogenesis is increased in multiple myeloma, suggesting that treatment with an antiangiogenic agent might be useful.
  • Among the new antiangiogenic drugs in development, Neovastat (AE-941; Aeterna Laboratories, Quebec City, Canada) can be classified as a naturally occurring multifunctional antiangiogenic agent.
  • Oral administration of Neovastat in mice with subcutaneous grafted breast cancer (DA3) cells showed a significant reduction in tumor volume.
  • Neovastat also decreased the number of lung metastases in the Lewis lung carcinoma model.
  • Furthermore, no treatment-related mortality or loss of body weight was observed.
  • In the oncology field, 482 patients have received Neovastat, of which 146 with solid tumors were exposed to the drug for more than 6 months.
  • A phase III double-blind placebo-controlled study is being conducted to evaluate the efficacy of Neovastat in addition to induction chemotherapy/radiotherapy combined modality treatment in patients with unresectable non-small cell lung cancer stage IIIA and IIIB.
  • A second phase III randomized, double-blind placebo-controlled study evaluates the efficacy of Neovastat as a monotherapy in metastatic renal cell carcinoma patients who have progressed following a first-line immunotherapy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Bone Marrow / blood supply. Bone Marrow / drug effects. Multiple Myeloma / drug therapy. Tissue Extracts / therapeutic use
  • [MeSH-minor] Animals. Cartilage / chemistry. Clinical Trials as Topic. Drug Screening Assays, Antitumor. Humans. Kidney Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Metastasis / drug therapy. Neovascularization, Pathologic. Sharks

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11740820.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Tissue Extracts; 0 / shark cartilage extract
  • [Number-of-references] 42
  •  go-up   go-down


49. Yoshizawa H, Tanaka J, Kagamu H, Maruyama Y, Miyao H, Ito K, Sato T, Iwashima A, Suzuki E, Gejyo F: Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer; 2003 Sep 1;89(5):803-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer.
  • A study was undertaken to determine the maximum tolerated dose, the dose-limiting toxicities and the response rate of carboplatin and 5-fluorouracil administered daily with concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer.
  • In a phase I/II clinical trial, patients with histologically documented, unresectable stage IIIA or IIIB non-small-cell lung cancer (NSCLC) were enrolled.
  • Radiotherapy, with a total dose of 60 Gy, was delivered in 30 fractions on days 1-40.
  • The median survival time was 19.8 months, with a survival rate of 70% at 1 year, 36.7% at 2 years.
  • The major toxicities of treatment were neutropenia (>or=grade 3, 87.9%) and thrombocytopenia (>or=grade 3, 23.3%).
  • This combined therapy for locally advanced non-small-cell lung cancer is promising and shows acceptable toxicity.
  • [MeSH-major] Carboplatin / administration & dosage. Carcinoma, Non-Small-Cell Lung / therapy. Fluorouracil / administration & dosage. Lung Neoplasms / therapy. Radiation-Sensitizing Agents / administration & dosage
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / toxicity. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1999 Aug;52(2):137-48 [10577699.001]
  • [Cites] Lung Cancer. 1994 Mar;10 Suppl 1:S239-44 [8087515.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1281-9 [11728688.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):134-9 [12007951.001]
  • [Cites] AJR Am J Roentgenol. 1976 Feb;126(2):229-35 [175693.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Nov;8(11):1923-33 [6818194.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):539-47 [3009368.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5 [3466165.001]
  • [Cites] Radiother Oncol. 1987 Jun;9(2):157-65 [3303163.001]
  • [Cites] Breast Cancer Res Treat. 1987 Nov;10(2):145-9 [3427223.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Feb;25(2):173-6 [2649374.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1543-55 [2167952.001]
  • [Cites] N Engl J Med. 1990 Oct 4;323(14):940-5 [2169587.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1183-90 [1646194.001]
  • [Cites] N Engl J Med. 1992 Feb 20;326(8):524-30 [1310160.001]
  • [Cites] J Natl Cancer Inst. 1992 Jan 1;84(1):58 [1310747.001]
  • [Cites] Oncology. 1992;49 Suppl 1:71-6; discussion 77 [1323815.001]
  • [Cites] Semin Oncol. 1992 Aug;19(4 Suppl 11):2-7 [1509277.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):452-8 [7844608.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):819-25 [7860394.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 1;87(3):198-205 [7707407.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1065-70 [8648358.001]
  • [Cites] J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5 [8780630.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6 Suppl 16):113-6 [9007136.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):257-62 [9683303.001]
  • [Cites] Ann Oncol. 1992 Aug;3 Suppl 3:33-7 [1327081.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6501-6 [1423296.001]
  • [Cites] Anticancer Res. 1994 Mar-Apr;14(2A):461-4 [8017848.001]
  • [Cites] Semin Oncol. 1994 Jun;21(3 Suppl 6):79-90 [8052878.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):883-7 [11429215.001]
  • (PMID = 12942108.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2394482
  •  go-up   go-down






Advertisement